Elvitegravir
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314218

CAS#: 697761-98-1

Description: Elvitegravir (EVG, formerly GS-9137) is an integrase inhibitor used to treat HIV infection. The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor. (Source: http://en.wikipedia.org/wiki/Elvitegravir).


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 650
1g
USD 1950
10g
USD 4950
100g
Ask price
Size
Price

25mg
USD 250
200mg
USD 850
2g
USD 2950
20g
USD 6950
Size
Price

50mg
USD 450
500mg
USD 1250
5g
USD 3950
50g
USD 9950

Elvitegravir, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 314218
Name: Elvitegravir
CAS#: 697761-98-1
Chemical Formula: C23H23ClFNO5
Exact Mass: 447.12488
Molecular Weight: 447.88
Elemental Analysis: C, 61.68; H, 5.18; Cl, 7.92; F, 4.24; N, 3.13; O, 17.86


Synonym: GS9137; GS9137; GS9137; EVG; Elvitegravir; brand name: Stribild.

IUPAC/Chemical Name: 6-[(3-Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid

InChi Key: JUZYLCPPVHEVSV-LJQANCHMSA-N

InChi Code: InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1

SMILES Code: O=C(C1=CN([C@@H](C(C)C)CO)C2=C(C=C(CC3=CC=CC(Cl)=C3F)C(OC)=C2)C1=O)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

 1: Pandey KK. Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS. HIV AIDS (Auckl). 2014 May 16;6:81-90. eCollection 2014. Review. PubMed PMID: 24876793; PubMed Central PMCID: PMC4037326.

2: Temesgen Z. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection. Drugs Today (Barc). 2012 Dec;48(12):765-71. doi: 10.1358/dot.2012.48.12.1895682. Review. PubMed PMID: 23243633.

3: Olin JL, Spooner LM, Klibanov OM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann Pharmacother. 2012 Dec;46(12):1671-7. doi: 10.1345/aph.1R468. Epub 2012 Nov 7. Review. PubMed PMID: 23136357.

4: Wills T, Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs. 2012 Mar;21(3):395-401. doi: 10.1517/13543784.2012.658914. Epub 2012 Feb 10. Review. PubMed PMID: 22321026.

5: Lampiris HW. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti Infect Ther. 2012 Jan;10(1):13-20. doi: 10.1586/eri.11.157. Review. PubMed PMID: 22149610.

6: Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011 Apr;50(4):229-44. doi: 10.2165/11584570-000000000-00000. Review. PubMed PMID: 21348537.

7: Shimura K, Kodama EN. Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85. doi: 10.3851/IMP1397. Review. PubMed PMID: 19843978.

8: Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology. 2009 Mar 5;6:25. doi: 10.1186/1742-4690-6-25. Review. Erratum in: Retrovirology. 2009;6:33. PubMed PMID: 19265512; PubMed Central PMCID: PMC2660292.

9: Grant P, Zolopa A. Integrase inhibitors: a clinical review of raltegravir and elvitegravir. J HIV Ther. 2008 Jun;13(2):36-9. Review. PubMed PMID: 18953272.